Skip to main content

Pemigatinib Side Effects

Medically reviewed by Drugs.com. Last updated on May 25, 2022.

For the Consumer

Applies to pemigatinib: oral tablet

Side effects requiring immediate medical attention

Along with its needed effects, pemigatinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking pemigatinib:

More common

  • Bladder pain
  • bloody or cloudy urine
  • changes in the fingernails or toenails
  • confusion
  • decreased urination
  • diarrhea
  • difficult, burning, or painful urination
  • difficulty in breathing
  • dry eyes
  • dry mouth
  • frequent urge to urinate
  • increase in heart rate
  • irregular heartbeats
  • lightheadedness, dizziness, fainting
  • loosening of the fingernails
  • loss of appetite
  • lower back or side pain
  • mood or mental changes
  • muscle cramps in the hands, arms, feet, legs, or face
  • numbness and tingling around the mouth, fingertips, or feet
  • pain in the bones
  • rapid breathing
  • redness or soreness around the fingernails
  • seeing flashes or sparks of light
  • seeing floating spots before the eyes, or a veil or curtain across part of your vision
  • seizures
  • stomach cramps
  • sunken eyes
  • thirst
  • tremor
  • unusual tiredness or weakness
  • unusual weight loss
  • wrinkled skin

Less common

  • Pain or swelling in the arms or legs without any injury

Side effects not requiring immediate medical attention

Some side effects of pemigatinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Bloating or swelling of the face, arms, hands, lower legs, or feet
  • changes in taste
  • constipation
  • difficulty in moving
  • dry skin
  • hair loss
  • loss of taste
  • nausea
  • pain in the joints
  • rapid weight gain
  • redness, swelling, pain of the skin
  • scaling of the skin on the hands and feet
  • swelling or inflammation of the mouth
  • ulceration of the skin
  • vomiting

For Healthcare Professionals

Applies to pemigatinib: oral tablet

Hematologic

Very common (10% or more): Hemoglobin decreased (43%), lymphocytes decreased (36%), platelets decreased (28%), leukocytes increased (27%)[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (25%), back pain (20%), pain in extremity (19%)

Common (1% to 10%): Fractures, pathologic fractures (which include patients with and without cholangiocarcinoma)[Ref]

Ocular

Very common (10% or more): Dry eye (e.g., dry eye, keratitis, lacrimation increased, pinguecula, punctate keratitis) (25%)

Common (1% to 10%): retinal pigment epithelial detachment (RPED)[Ref]

Metabolic

Very common (10% or more): Hyperphosphatemia (94%), hypophosphatemia (68%), alanine aminotransferase increased (43%), aspartate aminotransferase increased (43%), calcium increased (43%), alkaline phosphatase increased (41%), creatinine increased (41%), sodium increased (39%), glucose increased (36%), albumin decreased (34%), anorexia (33%), urate increased (30%), bilirubin increased (26%), potassium decreased (26%), hypophosphatemia (23%), calcium decreased (17%), weight loss (16%), dehydration (15%), potassium increased (12%), glucose decreased (11%)[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (16%)[Ref]

Other

Very common (10% or more): Fatigue (42%), edema peripheral (18%), dysgeusia (40%), headache (16%)[Ref]

General

Serious adverse reactions in2% or greater of patients who received this drug included abdominal pain, pyrexia, cholangitis, pleural effusion, acute kidney injury, cholangitis infective, failure to thrive, hypercalcemia, hyponatremia, small intestinal obstruction, and urinary tract infection. Fatal adverse reactions occurred in 4.1% of patients, including failure to thrive, bile duct obstruction, cholangitis, sepsis, and pleural effusion[Ref]

Dermatologic

Very common (10% or more): Alopecia (49%), nail toxicity (e.g., nail disorder, nail discoloration, nail dystrophy, nail hypertrophy, nail ridging, nail infection,

onychalgia, onychoclasis, onycholysis, onychomadesis, onychomycosis, paronychia) (43%), dry skin (20%), palmar-plantar erythrodysesthesia syndrome (15%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (47%), nausea (40%), constipation (35%), stomatitis (35%), dry mouth (34%), vomiting (27%), abdominal pain (23%)[Ref]

References

1. "Product Information. Pemazyre (pemigatinib)." Incyte Corporation (2020):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.